Heron Therapeutics Statistics Share Statistics Heron Therapeutics has 153.33M
shares outstanding. The number of shares has increased by 0.59%
in one year.
Shares Outstanding 153.33M Shares Change (YoY) 0.59% Shares Change (QoQ) 0.15% Owned by Institutions (%) 81.29% Shares Floating 151.85M Failed to Deliver (FTD) Shares 2,460 FTD / Avg. Volume 0.14%
Short Selling Information The latest short interest is 32.96M, so 17.98% of the outstanding
shares have been sold short.
Short Interest 32.96M Short % of Shares Out 17.98% Short % of Float 22.26% Short Ratio (days to cover) 27.64
Valuation Ratios The PE ratio is -17.18 and the forward
PE ratio is 20.33.
Heron Therapeutics's PEG ratio is
0.19.
PE Ratio -17.18 Forward PE 20.33 PS Ratio 1.62 Forward PS 1 PB Ratio -6.93 P/FCF Ratio -9.62 PEG Ratio 0.19
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Heron Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.29,
with a Debt / Equity ratio of -5.28.
Current Ratio 2.29 Quick Ratio 1.7 Debt / Equity -5.28 Debt / EBITDA -35.16 Debt / FCF -7.33 Interest Coverage -1.91
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.18M Profits Per Employee $-111.31K Employee Count 122 Asset Turnover 0.62 Inventory Turnover 0.73
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -39.2% in the
last 52 weeks. The beta is 1.23, so Heron Therapeutics's
price volatility has been higher than the market average.
Beta 1.23 52-Week Price Change -39.2% 50-Day Moving Average 1.47 200-Day Moving Average 1.84 Relative Strength Index (RSI) 37.42 Average Volume (20 Days) 1,725,582
Income Statement In the last 12 months, Heron Therapeutics had revenue of 144.28M
and earned -13.58M
in profits. Earnings per share was -0.09.
Revenue 144.28M Gross Profit 105.64M Operating Income -11.53M Net Income -13.58M EBITDA -5.06M EBIT -7.55M Earnings Per Share (EPS) -0.09
Full Income Statement Balance Sheet The company has 25.8M in cash and 177.76M in
debt, giving a net cash position of -151.96M.
Cash & Cash Equivalents 25.8M Total Debt 177.76M Net Cash -151.96M Retained Earnings -1.92B Total Assets 232.09M Working Capital -47.68M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -22.53M
and capital expenditures -1.71M, giving a free cash flow of -24.23M.
Operating Cash Flow -22.53M Capital Expenditures -1.71M Free Cash Flow -24.23M FCF Per Share -0.16
Full Cash Flow Statement Margins Gross margin is 73.21%, with operating and profit margins of -7.99% and -9.41%.
Gross Margin 73.21% Operating Margin -7.99% Pretax Margin -9.41% Profit Margin -9.41% EBITDA Margin -3.5% EBIT Margin -7.99% FCF Margin -16.8%
Dividends & Yields HRTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for HRTX is $4.5,
which is 271.9% higher than the current price. The consensus rating is "Buy".
Price Target $4.5 Price Target Difference 271.9% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jan 13, 2014. It was a
backward
split with a ratio of 1:20.
Last Split Date Jan 13, 2014 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -10.66 Piotroski F-Score 3
